Surescripts terminated its relationship with ReMy Health, making it much harder for Amazon's PillPack to access patient medication data, according to CNBC.
PillPack had a deal with ReMy that allowed it to access patient prescription data collected by Surescripts.
In July, Surescripts accused ReMy of breaking the terms of their contract by giving "fraudulent information" to Surescipts to get the prescription data. In particular, Surescripts said that ReMy asked for data to send to "providers caring for patients in hospitals," when instead it was sending that information to PillPack.
At that time, Surescripts launched an investigation into ReMy's alleged fraudulent actions.
Surescripts said it found no clear evidence of patient privacy violation after the investigation. However, the e-prescribing company claims ReMy fraudulently requested data on patient health insurance and prescription price information to give to drug marketing websites, according to CNBC.
Surescripts said the volume of ReMy's fraudulent activity was small, but it will end the relationship for the "integrity of its network."
PillPack now must manually collect data from its patients by asking them directly for their prescription history and relying on them to remember it correctly.
The company said this could lead to errors, as people taking multiple medications often forget the names and dosages of their drugs.
PillPack told CNBC that it hopes it can work out a deal with Surescripts directly to access patient data.
"Surescripts’ allegations are completely unfounded. ReMy Health always acted in full compliance with our contracts with Surescripts, and we have never provided any data from the Surescripts network to pharmaceutical companies for marketing purposes," ReMy Health CEO Aaron Crittenden said in a statement to Becker's Hospital Review.